Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer Triple Negative
Interventions: DRUG: Mirvetuximab Soravtansine (IMGN853)
Sponsor: Duke University
Collaborators: National Comprehensive Cancer Network